Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | OXTR | P30559 | 3/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 5/20 | 0.36 |
| ▸ | MMP3 | P08254 | 4/20 | 0.36 |
| ▸ | MMP7 | P09237 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | MMP13 | P45452 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5743539 | 1.00 | HSD17B10 (0.39) | HSD17B10OXTRPTPN1AVPR1AMMP1 | |
| SCHEMBL4945424 | 1.00 | HSD17B10 (0.39) | HSD17B10OXTRPTPN1AVPR1AMMP1 | |
| SCHEMBL5946005 | 1.00 | HSD17B10 (0.39) | HSD17B10OXTRPTPN1AVPR1AMMP1 | |
| SCHEMBL4421983 | 1.00 | HSD17B10 (0.39) | HSD17B10OXTRPTPN1AVPR1AMMP1 | |
| SCHEMBL4945427 | 1.00 | HSD17B10 (0.39) | HSD17B10OXTRPTPN1AVPR1AMMP1 | |
| SCHEMBL4421987 | 1.00 | HSD17B10 (0.39) | HSD17B10OXTRPTPN1AVPR1AMMP1 | |
| SCHEMBL4941942 | 0.90 | MMP1 (0.40) | HSD17B10OXTRPTPN1AVPR1AMMP1 | |
| SCHEMBL4941935 | 0.90 | MMP1 (0.40) | HSD17B10OXTRPTPN1AVPR1AMMP1 | |
| SCHEMBL8342965 | 0.87 | HSD17B10 (0.40) | HSD17B10PTPN1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL4936035 | 0.86 | MMP1 (0.36) | HSD17B10PTPN1MMP1MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1532109-B1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS | MERCK SERONO SA (CH) | 2009-09-09 | — | — | EP | disclosed |
| US-7115754-B2 | Pyrrolidine derivatives as oxytocin antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-10-03 | — | — | US | disclosed |
| US-20060004020-A1 | Pyrrolidine derivatives as oxytocin antagonists | MERCK SERONO SA (CH) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004020-A1 | Pyrrolidine derivatives as oxytocin antagonists | OXTR, PRLHR, AVPR1A | HSD17B10 2526/4885OXTR 1/4885PTPN1 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.